| Literature DB >> 31523367 |
Sara Cruciani1, Sara Santaniello1, Andrea Montella1, Carlo Ventura2, Margherita Maioli1.
Abstract
Mesenchymal stem cells are undifferentiated cells able to acquire different phenotypes under specific stimuli. In vitro manipulation of these cells is focused on understanding stem cell behavior, proliferation and pluripotency. Latest advances in the field of stem cells concern epigenetics and its role in maintaining self-renewal and differentiation capabilities. Chemical and physical stimuli can modulate cell commitment, acting on gene expression of Oct-4, Sox-2 and Nanog, the main stemness markers, and tissue-lineage specific genes. This activation or repression is related to the activity of chromatin-remodeling factors and epigenetic regulators, new targets of many cell therapies. The aim of this review is to afford a view of the current state of in vitro and in vivo stem cell applications, highlighting the strategies used to influence stem cell commitment for current and future cell therapies. Identifying the molecular mechanisms controlling stem cell fate could open up novel strategies for tissue repairing processes and other clinical applications.Entities:
Keywords: Cell transplantation; Clinical practice; Epigenetics; In vitro differentiation; Physical stimuli; Self-renewal; Stem cell fate; Stem cells
Year: 2019 PMID: 31523367 PMCID: PMC6716083 DOI: 10.4252/wjsc.v11.i8.464
Source DB: PubMed Journal: World J Stem Cells ISSN: 1948-0210 Impact factor: 5.326
Figure 1Epigenetic regulation of stem cell fate. Chromatin remodeling affects cell behavior and regulates the balance between pluripotency and differentiation. HDACs: Histone deacetylases; Oct-4: Octamer-binding transcription factor 4; Sox-2: Sex determining region Y-box 2; NANOG: Nanog homeobox.
Figure 2Natural molecules and stem cell fate. Bioactive molecules induce cell proliferation and differentiation, reducing ROS production and apoptosis, through chromatin remodeling and epigenetic modifications. ROS: Reactive oxygen species; HDACs: Histone deacetylases.